18-Jun-2026
Ligand prices proposed $550M convertible senior notes offering
Seeking Alpha News (Mon, 22-Jun 7:33 AM ET)
Ligand Pharma Plans $550 Million Convertible Notes Offering
TipRanks (Mon, 22-Jun 7:27 AM ET)
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
Globe Newswire (Mon, 22-Jun 7:00 AM ET)
Insider Move at Ligand Pharma: Director Cashes In on Significant Stock Sale
TipRanks (Thu, 18-Jun 10:01 PM ET)
As corporate profit margins remain elevated, these mid-caps stand out
Seeking Alpha News (Thu, 18-Jun 9:25 AM ET)
Ligand Announces 2026 Investor Day in New York City
Globe Newswire (Wed, 10-Jun 7:00 AM ET)
Ligand to Participate in June Investor Conferences
Globe Newswire (Wed, 27-May 4:01 PM ET)
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Globe Newswire (Tue, 12-May 4:18 PM ET)
Ligand Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 7:00 AM ET)
Globe Newswire (Wed, 6-May 8:01 AM ET)
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ligand Pharmaceuticals trades on the NASDAQ stock market under the symbol LGND.
As of June 18, 2026, LGND stock price climbed to $274.88 with 514,481 million shares trading.
LGND has a beta of 0.76, meaning it tends to be less sensitive to market movements. LGND has a correlation of 0.07 to the broad based SPY ETF.
LGND has a market cap of $5.51 billion. This is considered a Mid Cap stock.
Last quarter Ligand Pharmaceuticals reported $52 million in Revenue and $1.63 earnings per share. This fell short of revenue expectation by $-7 million and missed earnings estimates by -$.01.
In the last 3 years, LGND traded as high as $276.20 and as low as $49.24.
The top ETF exchange traded funds that LGND belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
LGND has outperformed the market in the last year with a price return of +139.8% while the SPY ETF gained +26.9%. LGND has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +31.2% and +16.5%, respectively, while the SPY returned +13.5% and -1.1%, respectively.
LGND support price is $257.49 and resistance is $268.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGND shares will trade within this expected range on the day.